$3.56
+0.39(12.15%)
Mkt Cap $133M
$2.79
$8.32
52-Week Range
At a Glance
AI-generated6-K
Nyxoah reported fourth quarter 2025 net revenue of €5.6 million, representing 347% year-over-year growth, and full year 2025 net revenue of €10.0 million, up 122% year-over-year, driven by the first full quarter of U.S. commercialization following FDA approval in August 2025. The company had €48.0 million in cash, cash equivalents and financial assets at December 31, 2025, and expects U.S. net revenue to grow approximately 25% sequentially in Q1 and Q2 2026.$133M
Market Cap
$8M
Revenue
-$72M
Net Income
Employees183
Fundamentals
How The Business Makes Money
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Industry Medical - Instruments & Supplies
Activity
Company Profile
CIK0001857190
ISINBE0974358906
Phone32 1 022 23 55
AddressRue Edouard Belin 12, Mont-Saint-Guibert, 1435, BE
SEC EDGAR